Status:
UNKNOWN
Soluble ST2 and Cardiovascular Outcome
Lead Sponsor:
Nanjing Medical University
Conditions:
Cardiovascular Disease
Eligibility:
All Genders
18-90 years
Brief Summary
Cardiac surgery induces hemodynamic stress on the myocardium, and this process can be associated with significant cardiovascular morbidity and mortality. Soluble suppression of tumorigenicity 2 (sST2)...
Eligibility Criteria
Inclusion
- age ≥ 18 years
- Congenital heart disease requiring surgery
- Valvular heart disease requiring surgery
- Arrhythmia requiring surgery
- Aortic dissection requiring surgery
- Coronary heart disease requiring surgery
Exclusion
- age \<18 years
- pregnancy
- severe renal dysfunction (creatinine \>200µmol/L)
- not capable of understanding or signing informed consent.
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04460131
Start Date
January 1 2019
End Date
December 31 2025
Last Update
April 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The first affiliated hospital of nanjing medical university
Nanjing, Jiangsu, China, 210029